ReviR Therapeutics

ReviR Therapeutics (溪砾科技) is an AI-driven biotech startup founded in 2021 that develops oral small-molecule drugs targeting RNA to treat genetic diseases, particularly neurodegenerative and rare conditions like Huntington's disease, Charcot-Marie-Tooth disease (CMT), and ALS . Its core platform, VoyageR, applies machine learning and RNA structural biology to predict splicing targets, model molecular activity, and generate optimized drug candidates . The company positions its approach as an "oral gene therapy" alternative to traditional gene therapies, which face delivery challenges and require invasive administration .

ReviR has raised substantial venture backing across multiple rounds, including a $30 million Series A in July 2024 led by Dragonstone Capital with follow-on from 5Y Capital, CDH Investments, and Yael Capital, plus strategic investors XtalPi and the CMT Research Foundation . Earlier investors include BlueRun Ventures, Shunwei Capital, Sky9 Capital, and others . It maintains a close R&D partnership with XtalPi, combining ReviR's RNA platform with XtalPi's AI and robotics infrastructure to advance pipeline candidates toward clinical trials .